170 related articles for article (PubMed ID: 36442664)
1. Making Protein Degradation Visible: Discovery of Theranostic PROTACs for Detecting and Degrading NAMPT.
Cheng J; He S; Xu J; Huang M; Dong G; Sheng C
J Med Chem; 2022 Dec; 65(23):15725-15737. PubMed ID: 36442664
[TBL] [Abstract][Full Text] [Related]
2. Discovery of potent NAMPT-Targeting PROTACs using FK866 as the warhead.
Zhang P; Wang W; Guo M; Zhou L; Dong G; Xu D; Sheng C
Bioorg Med Chem Lett; 2023 Aug; 92():129393. PubMed ID: 37369332
[TBL] [Abstract][Full Text] [Related]
3. Discovery of Highly Potent Nicotinamide Phosphoribosyltransferase Degraders for Efficient Treatment of Ovarian Cancer.
Bi K; Cheng J; He S; Fang Y; Huang M; Sheng C; Dong G
J Med Chem; 2023 Jan; 66(1):1048-1062. PubMed ID: 36563407
[TBL] [Abstract][Full Text] [Related]
4. Photoswitchable PROTACs for Reversible and Spatiotemporal Regulation of NAMPT and NAD
Cheng J; Zhang J; He S; Li M; Dong G; Sheng C
Angew Chem Int Ed Engl; 2024 Mar; 63(12):e202315997. PubMed ID: 38282119
[TBL] [Abstract][Full Text] [Related]
5. Fluorescence theranostic PROTACs for real-time visualization of ERα degradation.
Wang X; Xin L; Deng X; Dong C; Hu G; Zhou HB
Eur J Med Chem; 2024 Mar; 267():116184. PubMed ID: 38320426
[TBL] [Abstract][Full Text] [Related]
6. Addressing the Enzyme-independent tumor-promoting function of NAMPT via PROTAC-mediated degradation.
Zhu X; Liu H; Chen L; Wu C; Liu X; Cang Y; Jiang B; Yang X; Fan G
Cell Chem Biol; 2022 Nov; 29(11):1616-1629.e12. PubMed ID: 36323324
[TBL] [Abstract][Full Text] [Related]
7. In situ albumin-binding and esterase-specifically cleaved BRD4-degrading PROTAC for targeted cancer therapy.
Cho H; Jeon SI; Shim MK; Ahn CH; Kim K
Biomaterials; 2023 Apr; 295():122038. PubMed ID: 36787659
[TBL] [Abstract][Full Text] [Related]
8. CRBN ligand expansion for hematopoietic prostaglandin D
Osawa H; Kurohara T; Ito T; Shibata N; Demizu Y
Bioorg Med Chem; 2023 Apr; 84():117259. PubMed ID: 37018877
[TBL] [Abstract][Full Text] [Related]
9. Drugtamer-PROTAC Conjugation Strategy for Targeted PROTAC Delivery and Synergistic Antitumor Therapy.
He S; Fang Y; Zhu Y; Ma Z; Dong G; Sheng C
Adv Sci (Weinh); 2024 Apr; ():e2401623. PubMed ID: 38639391
[TBL] [Abstract][Full Text] [Related]
10. Fluorescent and theranostic probes for imaging nicotinamide phosphoribosyl transferase (NAMPT).
Sun D; Dong G; Wu Y; Dong G; Du L; Li M; Sheng C
Eur J Med Chem; 2023 Feb; 248():115080. PubMed ID: 36608458
[TBL] [Abstract][Full Text] [Related]
11. Inhibition of nicotinamide phosphoribosyltransferase and depletion of nicotinamide adenine dinucleotide contribute to arsenic trioxide suppression of oral squamous cell carcinoma.
Wang XY; Wang JZ; Gao L; Zhang FY; Wang Q; Liu KJ; Xiang B
Toxicol Appl Pharmacol; 2017 Sep; 331():54-61. PubMed ID: 28501332
[TBL] [Abstract][Full Text] [Related]
12. A fluorometric assay for high-throughput screening targeting nicotinamide phosphoribosyltransferase.
Zhang RY; Qin Y; Lv XQ; Wang P; Xu TY; Zhang L; Miao CY
Anal Biochem; 2011 May; 412(1):18-25. PubMed ID: 21211508
[TBL] [Abstract][Full Text] [Related]
13. Radiotherapy-Triggered Proteolysis Targeting Chimera Prodrug Activation in Tumors.
Yang C; Yang Y; Li Y; Ni Q; Li J
J Am Chem Soc; 2023 Jan; 145(1):385-391. PubMed ID: 36542856
[TBL] [Abstract][Full Text] [Related]
14. Rational Design of Bioorthogonally Activatable PROTAC for Tumor-Targeted Protein Degradation.
Bi T; Liang P; Zhou Y; Wang H; Huang R; Sun Q; Shen H; Yang S; Ren W; Liu Z
J Med Chem; 2023 Nov; 66(21):14843-14852. PubMed ID: 37871321
[TBL] [Abstract][Full Text] [Related]
15. Design, synthesis, and biological evaluation of novel protopanoxadiol derivatives based PROTACs technology for the treatment of lung cancer.
Wang P; Zhu H; Liu J; Xie S; Xu S; Chen Y; Xu J; Zhao Y; Zhu Z; Xu J
Bioorg Chem; 2023 Feb; 131():106327. PubMed ID: 36549254
[TBL] [Abstract][Full Text] [Related]
16. Discovery of the GSH responsive "Y-PROTACs" targeting ALK and CDK4/6 as a potential treatment for cancer.
Wang S; Luo D; Pu C; Ma X; Zhang H; Feng Z; Deng R; Yu S; Liu Y; Huang Q; Li R
Eur J Med Chem; 2023 Feb; 248():115082. PubMed ID: 36628851
[TBL] [Abstract][Full Text] [Related]
17. Solid-Phase Synthesis of Cereblon-Recruiting Selective Histone Deacetylase 6 Degraders (HDAC6 PROTACs) with Antileukemic Activity.
Sinatra L; Yang J; Schliehe-Diecks J; Dienstbier N; Vogt M; Gebing P; Bachmann LM; Sönnichsen M; Lenz T; Stühler K; Schöler A; Borkhardt A; Bhatia S; Hansen FK
J Med Chem; 2022 Dec; 65(24):16860-16878. PubMed ID: 36473103
[TBL] [Abstract][Full Text] [Related]
18. Anticancer Activities of Novel Nicotinamide Phosphoribosyltransferase Inhibitors in Hematological Malignancies.
Biniecka P; Matsumoto S; Belotti A; Joussot J; Bai JF; Majjigapu SR; Thoueille P; Spaggiari D; Desfontaine V; Piacente F; Bruzzone S; Cea M; Decosterd LA; Vogel P; Nencioni A; Duchosal MA; Nahimana A
Molecules; 2023 Feb; 28(4):. PubMed ID: 36838885
[TBL] [Abstract][Full Text] [Related]
19. Structure-based identification of ureas as novel nicotinamide phosphoribosyltransferase (Nampt) inhibitors.
Zheng X; Bauer P; Baumeister T; Buckmelter AJ; Caligiuri M; Clodfelter KH; Han B; Ho YC; Kley N; Lin J; Reynolds DJ; Sharma G; Smith CC; Wang Z; Dragovich PS; Oh A; Wang W; Zak M; Gunzner-Toste J; Zhao G; Yuen PW; Bair KW
J Med Chem; 2013 Jun; 56(12):4921-37. PubMed ID: 23617784
[TBL] [Abstract][Full Text] [Related]
20. Discovery of potent and efficacious urea-containing nicotinamide phosphoribosyltransferase (NAMPT) inhibitors with reduced CYP2C9 inhibition properties.
Gunzner-Toste J; Zhao G; Bauer P; Baumeister T; Buckmelter AJ; Caligiuri M; Clodfelter KH; Fu B; Han B; Ho YC; Kley N; Liang X; Liederer BM; Lin J; Mukadam S; O'Brien T; Oh A; Reynolds DJ; Sharma G; Skelton N; Smith CC; Sodhi J; Wang W; Wang Z; Xiao Y; Yuen PW; Zak M; Zhang L; Zheng X; Bair KW; Dragovich PS
Bioorg Med Chem Lett; 2013 Jun; 23(12):3531-8. PubMed ID: 23668988
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
